Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 26, 2026
Event Date: January 23, 2026
Context: The Company entered into warrant exercise inducement agreements to raise capital for clinical development and working capital. A reverse stock split (one-for-four) was effected on January 28, 2026.
Key Financial Metrics
- Gross Proceeds: Approximately $7.3 million from the exercise of Existing Warrants.
- Transaction Fees: 8% of aggregate gross proceeds payable to Roth Capital Partners, LLC, plus expense reimbursement.
- Warrant Exercise Price: $0.86 per share (pre-split) / $3.44 per share (post-split).
- Shares Issued (Existing Warrants): 2,136,251 shares of common stock (post-split).
- New Warrants Issued (Class J): 4,272,500 warrants (post-split) exercisable for five years post-approval.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or margins.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or current liquidity balances.
Material Changes
The primary material change is the entry into definitive agreements to induce the exercise of 8,544,999 pre-split (2,136,251 post-split) Class I Common Stock Warrants. In exchange, the Company issued 17,089,998 pre-split (4,272,500 post-split) Class J Common Stock Warrants. This transaction supersedes a prior press release dated January 23, 2026, which included a third investor that ultimately withdrew its proposed investment.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds will fund clinical development plans, working capital, and general corporate purposes.
- Regulatory Requirements: The Company must file a resale registration statement on Form S-3 within twenty days of closing. Failure to do so may result in financial penalties.
- Stockholder Approval: The Class J Warrants are not exercisable until stockholder approval is obtained.
- Risks: Risks include the ability to timely file the S-3 registration, clinical trial enrollment and outcomes, adverse safety events, regulatory approval uncertainties, and maintaining NASDAQ listing status.
Investor Verification Checklist
- Verify the effectiveness of the Form S-3 registration statement for the resale of shares underlying the Class J Warrants within the 20-day deadline.
- Confirm the status of stockholder approval required to make the Class J Warrants exercisable.
- Review the impact of the 8% financial advisory fee on the net cash proceeds available for operations.
- Monitor the Company's cash runway and liquidity position following the $7.3 million gross raise.
- Track the progress of clinical development plans funded by this transaction.